Physician profile
Michael M Langer
NPI 1043280480
$51,141.28
in general payments reported to CMS, 2019-2025
28 companies · $19K in 2025
The $19K reported for 2025 was more than what a typical Magnetic Resonance Imaging (Mri) provider received nationally (typical 2025 total: $9,991).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $553 · 2021: $1,432 · 2022: $367 · 2023: $16K · 2024: $12K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $4,414 · Travel and Lodging: $4,101 · Consulting Fee: $243 · Education: $12.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,499.00 |
| Food and Beverage | $4,413.71 |
| Travel and Lodging | $4,100.70 |
| Consulting Fee | $242.50 |
| Education | $12.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $44,315.18 | 2019-2025 | Camzyos |
| Heartflow, INC. | $797.12 | 2023-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $744.78 | 2019-2024 | Xarelto |
| Amgen INC. | $696.89 | 2019-2022 | |
| Boston Scientific Corporation | $680.32 | 2019-2024 | Watchman Flx |
| Abbott Laboratories | $652.53 | 2019-2025 | Aveir, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $469.32 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.90 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $352.82 | 2021-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $267.27 | 2023-2024 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $212.56 | 2019-2020 | |
| Pfizer INC. | $198.29 | 2019-2024 | |
| Amarin Pharma, INC. | $181.14 | 2019-2021 | |
| Esperion Therapeutics, INC. | $162.04 | 2021 | |
| Shockwave Medical, INC | $154.02 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $126.19 | 2023 | Impella |
| Medtronic, INC. | $122.38 | 2021 | |
| Vifor Pharma, INC. | $120.79 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $120.41 | 2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $112.76 | 2023-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $95.22 | 2019-2020 | |
| Cvrx, INC. | $48.16 | 2022 | |
| Lundbeck LLC | $32.53 | 2019 | |
| Akcea Therapeutics, INC. | $29.44 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.04 | 2021 | |
| Csl Behring | $17.99 | 2019 | |
| Siemens Medical Solutions USA, INC. | $17.84 | 2025 | Magnetom Altea |
| Regeneron Healthcare Solutions, INC. | $16.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Langer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.